Secord, A. A., McCollum, M., Davidson, B., Broadwater, G., Squatrito, R., Havrilesky, L., … Duska, L. (2018). PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER. In INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (Vol. 28, pp. 457–457). BMJ PUBLISHING GROUP.

Secord, A Alvarez, M. McCollum, B. Davidson, G. Broadwater, R. Squatrito, L. Havrilesky, A. Gabel, A. Nixon, and L. Duska. “PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER.” In INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 28:457–457. BMJ PUBLISHING GROUP, 2018.

Secord AA, McCollum M, Davidson B, Broadwater G, Squatrito R, Havrilesky L, et al. PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER. In: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. BMJ PUBLISHING GROUP; 2018. p. 457–457.

Secord, A. Alvarez, et al. “PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER.” INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 28, BMJ PUBLISHING GROUP, 2018, pp. 457–457.

Secord AA, McCollum M, Davidson B, Broadwater G, Squatrito R, Havrilesky L, Gabel A, Nixon A, Duska L. PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. BMJ PUBLISHING GROUP; 2018. p. 457–457.